EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

BACKGROUND: Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between EGFR expression and clinical outcome in the North...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Cancer
Glavni autori: Cheng, H, Ballman, K, Vassilakopoulou, M, Dueck, A C, Reinholz, M M, Tenner, K, Gralow, J, Hudis, C, Davidson, N E, Fountzilas, G, McCullough, A E, Chen, B, Psyrri, A, Rimm, D L, Perez, E A
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2014
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453859/
https://ncbi.nlm.nih.gov/pubmed/25117817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.442
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items